INTRODUCTION
Bone turnover may be assessed by the measurement of enzymes or matrix proteins produced by osteoblasts (which form bone) or osteoclasts (which resorb bone).' The introduction of reliable, specific tests for the biochemical markers of bone metabolism would aid in the clinical management of metabolic bone diseases, including osteoporosis.
Osteocalcin, also known as bone Gla protein, is a marker of bone formation. It is a vitamin Kand vitamin O-dependent protein produced by osteoblasts and is the most abundant and most widely studied of the non-collagenous proteins in bone.? 4 FIGURE I. Diagram of the secondary structure of osteocalcin. G/a residues are present at positions 17. 21 and 24 and a disulphide bridge is present hetween residues 23 and 29. other proteins being matrix Gla protein" and protein S."
Vitamin K 1 or phylloquinone (a lipid-soluble vitamin better known for its association with the coagulation cascade) is an essential co-factor for the post-translational y-carboxylation of osteocalcin. During carboxylation, a second carboxyl group is added to specific glutamyl residues (Glu) at positions 17, 21 and 24 forming ycarboxyglutamyl residues (Gla) (see Fig. 2 ). This modification leads to a conformational change, stabilizing the IX-helical portion of the protein and conferring a greater affinity for calcium and hydroxyapatite.'! There is no homology between the mature osteocalcin protein and the vitamin K-dependent
STRUCTURE OF OSTEOCALCIN
Osteocalcin is a 49-residue (5,8 kDa) polypeptide which is highly conserved between species. In humans the osteocalcin gene is located on chromosome I (I q25-q31) and is regulated at the transcriptional level by 1,25-dihydroxyvitamin 0 3 • 5
Osteocalcin is synthesized as an 11 kDa preproosteocalcin of 98 residues. This molecule consists of three parts, a 23-residue signal peptide that is cleaved during translation, a 26residue propeptide that targets the protein for y carboxylation and the 49-residue mature protein." 7 The mature osteocalcin peptide consists of two anti-parallel IX-helical domains (residues 16~25 and 3Q..41) connected by a {J turn (residues 26-29). There are two further {3 turns and a fJ-sheet structure at the C-terminal end. The structure is stabilized by a CYS2rCYS2d isulphide bond (see Fig. 1 ).8."
..CARBOXYLATION OF OSTEOCALCIN
Osteocalcin is one of three known vitamin Kdependent proteins produced by osteoblasts, the coagulation factors, but there is a region of homology in the propeptides of these proteins.'?
SYNTHESIS AND CATABOLISM OF OSTEOCALCIN
Osteocalcin has long been accepted as an osteoblast-specific prodUCt. 3 . 13 . 14 Recently, however, there have been reports of megakaryocyte and adipocyte expression of osteocalcin mRNA and protein. 15 ,16 It should be noted that this expression has been reported in vitro, in immortalized cell lines, and not in vivo.
The actual function of osteocalcin is not known, but the 'osteocalcin knockout' mouse reported by Ducy et al." showed no abnormal phenotype until 6 months of age, at which time there was a marked increase in bone formation. This suggests that osteocalcin may have a role in regulation of osteoblast function.
The majority of osteocalcin secreted by the osteoblast is deposited in extracellular bone matrix; serum osteocalcin represents the fraction of total osteocalcin that has not adsorbed to hydroxyapatite.
HETEROGENEITY OF CIRCULATING OSTEOCALCIN
The heterogeneity of circulating osteocalcin was first reported in 1985. IH Serum osteocalcin has a short half-life and is hydrolysed in the kidney and Iiver. 19 The C-terminal fragment is easily cleaved and the N-terminal mid-fragment shows greater apparent stability. Residues 19-20 and 43-44 are susceptible to tryptic hydrolysis.P' It has been proposed that the arginylarginyl
Measurement of osteocalcin 433
residues at positions 19-20 are protected from proteolysis by their incorporation in the Gla helix? or that this protection is derived from the highly negatively charged y-carboxyglutamyl residues at positions 17, 21 and 24. 21 The residues at positions 43 and 44, which are highly conserved between species, are probably more labile due to their incorporation in the Cterminal p-sheet. 22 Garnero et alY used monoclonal antibodies to identify circulating fragments in healthy subjects and patients with metabolic bone disease (see Fig. 3 ). The intact molecule and the N-terminal mid-fragment were the most abundant immunoreactive forms in normal and osteoporotic subjects. Additionally, they found that there was an increase in the Nterminal mid-fragment in patients with Paget's disease, and concentrations of both intact and fragmented osteocalcin were increased in patients with chronic renal failure. Different metabolic bone diseases may have different characteristic patterns of immunoreactive forms of osteocalcin-t-" highlighting the possibility of measuring different forms in the clinical investigation of bone pathologies. The detection of intact osteocalcin or fragments is an important issue in the choice of a commercial assay for the clinical laboratory. Assays detecting only intact osteocalcin will be particularly sensitive to in vitro degradation, whilst assays detecting fragments may, depending on the fragments recognized, overestimate the concentration of intact osieocalcin." Another difficulty arises from recent studies which suggest that the specificity of commercial assays may differ from that claimed by the manufacturers (see Table 1 
CLINICAL RELEVANCE OF SERUM OSTEOCALCIN
Bone markers are classified according to whether they reflect bone formation or resorption. As stated earlier, osteocalcin is a marker of bone formation and in some situations, such as corticosteroid therapy, is considered to be a more sensitive marker than serum alkaline phosphatase activity." Serum osteocalcin reflects the 10-40% of osteocalcin produced that is not incorporated into the bone matrix." It is postulated that newly synthesized osteocalcin is released into the circulation as the intact (1-49) molecule." Osteocalcin fragments may be derived from bone resorption and catabolism of the molecule in vivo before clearance by metalloproteases in the kidneys and the liver." Quantitative bone histomorphometry and combined calcium balance/calcium kinetics studies have validated the use of osteocalcin as a marker of bone forrnation.J'r "
In postmenopausal women serum osteocalcin levels correlate significantly with both the bone formation rate and the kinetically determined calcium accretion rate, but not with bone resorption.l'v"
Postmenopausal osteoporosis
It has been suggested that there are discrete groups of postmenopausal osteoporotic women, with normal, high or low bone formation." In support of this, osteocalcin concentrations have been reported as similar, higher or lower than normal age-matched controls.v-"
An elevation of 10% has been reported in the mean osteocalcin concentration in postmenopausal osteoporosis, in contrast to the greater elevation reported in bone resorption markers, such as deoxypyridinoline, which is increased by Ann Clin Biochem 2000: 37 50%.33 Serum osteocalcin concentrations correlate with the rate of bone loss from the distal forearm." However, the overlap of results is too great for the diagnosis of osteoporosis in individuals and the scatter around the regression line is too great to identify individuals with accelerated bone loss." Monitoring osteocalcin concentration may be useful in determining the response to treatment for metabolic bone diseases or the prediction of bone loss in postmenopausal women. 3 1. [38] [39] [40] Osteomalacia In osteomalacia, serum osteocalcin correlates with parameters of osteoid formation and is significantly elevated. This is due to secondary hyperparathyroidism and to the defect in mineralization in osteomalacia, which prevents the incorporation of de novo osteocalcin into the bone and results in raised serum concentration."
Hyper-and hypoparathyroidism Circulating osteocalcin is increased in hyperparathyroidism and decreased in hypoparathyroidism." Osteocalcin concentration correlates with parathyroid hormone concentration better than does serum alkaline phosphatase activity and urinary hydroxyproline:creatinine ratio.f Paget's disease of bone In Paget's disease, serum osteocalcin concentrations are significantly raised. However, the magnitude of this is smaller than for other markers of bone formation such as bone alkaline phosphatase. The reason for this discrepancy is not known, but it could relate to the greater affinity of osteocalcin for the woven bone of Paget's disease. 39 
Other conditions
The effects of other pathological conditions on osteocalcin are listed in Table 2 .
Therapeutic agents Some therapeutic agents affect circulating con-centr~tions of osteocalcin. 1,25-dihydroxyvitamin D.J stll~ulates osteocalcin production." A calcitriol stimulation test has been proposed by Duda et al., 58 in which 2 JIg calcitriol per day is given orally and the osteocalcin response at 7 days is used to assess osteoblast responsiveness. Glucocorticoids, on the other hand, decrease serum osteocalcin within a day of starting therapy and t~e effect is dose-dependent.59-64 Low osteocalcm. concentration has been used to identify p.atlents with adrenal insufficiency given exces-SIVe replacement doses.f It has been suggested that the increase in osteocalcin concentrations een in anticonvulsant therapy may reflect an IDcrease in bone turnover, which may contribute to osteopoenia, a complication of anticonvulsant therapy in children."
CirCUlatingosteocalcin is decreased in patients receiving heparin'" and some, but not all, studies ?fwarfarin-treated patients also show a decrease ID osteocalcin. 68.69 Coumarins such as warfarin are considered further in the discussion of undercarboxylated osteocalcin below.
UNDERCARBOXYLATED OSTEOCALCIN
Low concentrations of serum vitamin K 1 (P~Ylloquinone) and vitamin K 2 (the mena-qUlnones) have been associated with bone fragility and increased risk of fracture.P:"
Osteocalcin is a vitamin K-dependent protein and the percentage of osteocalcin that has not undergone modification by the vitamin Kdependent carboxylase has recently been the focus of much attention.
. C.oncentration of undercarboxylated osteocalern IS significantly increased with age." but cañ e normalized by vitamin K supplementa-tIon.7 5. 76 In addition, undercarboxylated osteo-calcin correlates with bone mineral density at the femoral neck." Furthermore, the fraction of undercarboxylated osteocalcin has been suggested to be a predictor of hip fracture in elderly women.P:" Early studies of undercarboxylated osteocalcin were criticized because the populations studied were predominantly institutionalized women, who may have had inadequate nutrition, a recognized factor in osteoporosis in the elderly.80.81 This issue has recently been addressed and a recent report confirms undercarboxylated osteocalcin as an independent predictor of hip fracture in a population of ambulatory elderly women, 90% of whom were free-living." Total osteocalcin concentration is not predictive of hip fracture, suggesting that the association between undercarboxylated osteocalcin and hip fracture is not due to increased bone formation. This may indicate that undercarboxylated osteocalcin is an indicator of poor bone quality rather than an indicator of bone turnover. Another suggestion that requires further investigation is that undercarboxylated osteocalcin may inhibit osteoblast function to a greater degree than the carboxylated form of the protein.P Warfarin and other coumarin derivatives are used clinically as anticoagulants. These drugs inhibit the vitamin K-dependent carboxylase, thus preventing the post-translational modification of the vitamin K-dependent clotting factors produced by the liver. The carboxylation of osteocalcin is impaired in warfarin-treated patients," i.e. the percentage of undercarboxylated osteocalcin is higher in these subjects, and this may have implications for their bone health.
HISTORICAL PERSPECTIVE OF OSTEOCALCIN ASSAYS
Many immunoassays have been developed to detect human osteocalcin. Bovine osteoca1cin is more abundant and more stable than human osteocalcin. As osteocalcin is highly conserved between species, many assays are directed against bovine osteocalcin.
In 1980 Price et al. described the first assay for osteocalcin." This assay employed a rabbit antibody directed against calf osteocalcin to detect human osteocalcin in plasma, with a sensitivity of 0·1 ng.
By 1985 there were several methods for the determination of osteocalcin. Gundberg et al. compared two commercial kits with an in-house assay and showed a good correlation between methods when the assay standard and normal ranges were used." This was the first report to draw attention to differences between methods and to suggest that one assay cannot be substituted for another. In 1986 Tanaka et al. reported the first enzyme immunoassay (EIA) developed for osteocalcin." This assay was based on competition of 'sample' osteocalcin and fJ-galactosidase-labelled bovine osteocalcin for a rabbit polyclonal anti-osteocalcin antibody. It gave a good recovery and correlated well with radioimmunoassay (RIA).
There are now several commercial immunoassays available in RIA, immunoradiometric assay (IRMA) and enzyme immunoassay (ELISA) formats for the detection of total (fully and under-carboxylated) osteocalcin. Some of these assays are described in more detail below.
The carboxylation of osteocalcin confers a greater affinity for hydroxyapatite, and Price et al. demonstrated that undercarboxylated osteocalcin can be measured by an indirect method based on this property." Typically, total osteocalcin is measured by immunoassay followed by incubation with hydroxyapatite and centrifugation. The supernatant, which contains osteocalcin that has not adsorbed to hydroxyapatite (i.e, undercarboxylated osteocalcin) is then measured using the same immunoassay. The results of this procedure can be expressed either as absolute concentrations or as a ratio of undercarboxylated to carboxylated osteocalcin. The method is still susceptible to problems associated with osteocalcin assays and nonspecific binding to hydroxyapatite may occur.f but it has been utilized in many studies and is well characterized. Barium sulphate has been proposed as an alternative to hydroxyapatite for this procedure."
Recently, monoclonal antibodies have been developed which are claimed to be specific for undercarboxylated osteocalcin.v" Vergnaud et a/. reported a significant correlation (r = 0,82) between results obtained with an ELISA based on Ann Clin Biochem 2000: 37 these antibodies and the hydroxyapatite method and a low (5%) rate of cross-reactivity of the undercarboxylated osteocalcin specificantibodies with carboxylated osteocalcin.v-" A commercial immunoassay based on monoclonal antibodies, for the measurement of undercarboxylated osteocalcin, is now available (see Table 4 ).
These are exciting developments that will allow the measurement of undercarboxylated osteocalcin without use of the cumbersome and time-consuming hydroxyapatite method. However, these assays have not been fully characterized and further work will be required before they are accepted for widespread use.
There is no definitive or reference method for the measurement of either total or undercarboxylated osteocalcin in serum or plasma.
COMMERCIAL ASSAYS FOR OSTEOCALCIN
There are many commercial assays available for the measurement of osteocalcin. A selection, together with their performance characteristics, is shown in Tables 3 and 4.
STANDARDIZATION OF METHODS
Several studies have compared commercial assays; all have found a marked difference between methods irrespective of whether they were commercial kits or in-house assays.
In 1985 Gundberg et a/. demonstrated that three different assays gave widely differing results for identical samples; nevertheless the results were consistent when the reference ranges for the different assays were taken into account. 18 In 1990 Delmas and co-workers" highlighted the poor comparability of osteocalcin assays in a series of blinded lyophilized serum samples and a lyophilized reference standard analysed by eight in-house assays and two well-characterized commercial assays (see Fig. 4 ). Different assays were found to have different absolute concentrations of osteocalcin, sometimes differing by up to 50%. However, all of the assays gave acceptable results when compared by assay-to-assay correlations and when the results were expressed as a percentage of the mean of two controls." A similar analysis of commercially available assays, which used Z scores (Z score = sample osteocalcin -assay mean osteocalcin/Slr) to compare the different kits, found that this procedure reduced the differences between results." The divergent results from different assays arise from several 
SAMPLE STABILITY AND HANDLING
Osteocalcin is markedly unstable in vitro,23.Yl rapidly degrading in samples at room temperature and at 4°C. 20 . n Garnero et al. reported an in vitro degradation of 17% of intact osteocalcin over 2 h incubation at room temperature." This group also described at 4% in vitro degradation of intact and N-terminal mid-fragment after 2-h incubation at room temperature. This instability may occur in samples, standards or tracer and it has been suggested that there may even be degradation of these during the assay procedure itself.24
Protease inhibitors may reduce deterioration of osteocalcin in samples,B,93 but it is recommended that samples are kept at 4°C immediately upon venepuncture, serum or plasma separated as soon as possible, and samples frozen until assay, For short-term storage e.g. I month, freezing at -20°C will suffice," but for long-term storage it is advisable to store samples at -70°C (see Fig. 5 ).
Osteocalcin is sensitive to freeze-thaw cycles and haemolysis. Repeated freeze-thaw cycles have been shown to reduce immunoreactivity by up to 40%.18,20,94 Haemolysis decreases apparent osteocalcin concentrations in both in-house and commercial assays, possibly owing to proteolysis by enzymes released from lysed red blood cells."
Most commercial assays measure osteocalcin in either serum or plasma, but the anticoagulant used in plasma samples may affect the results obtained, In particular, potassium oxalate/ sodium fluoride should be avoided." Furthermore, some commercial assays may also be sensitive to calcium ions, Unfortunately, the manufacturers do not make available information on the calcium content of their buffers." This has clear implications for samples from patients with differing clinical conditions and samples collected using EDTA or other calcium chelators,
In this laboratory, samples for osteocalcin measurement are separated within 1h of venepuncture and immediately frozen at -20°C, For long-term storage they are then transferred to a freezer at -70°C.
QUALITY CONTROL
The National Supra regional Assay and Advisory Service in England measures biochemical markers of bone metabolism. An External Quality Assessment Programme (EQAS) has been initiated to monitor the performance of these and other laboratories that offer assays of biochemical markers of bone metabolism. Osteocalcin will be included in the scheme in 1999. 96 Ann Clin Biochem 2000: 37
The lack of international standards for osteocalcin has hindered progress in the standardization of commercial assays and at present there is no consensus among laboratories concerning the fragment(s) of osteocalcin that are of greatest clinical use.
BIOLOGICAL VARIABILITY
Serum osteocalcin has been shown to have a large diurnal variation (peaking in the early morning at approximately 0400 h).35,95,97 Samples for osteocalcin determination should be collected at the same time of day if comparisons between serial samples are required. There is also a seasonal variation, with concentrations declining from January to July and then increasing to a peak in winter. 98 ,99 During the menstrual cycle osteocalcin reaches its highest levels during the luteal phase.f Serum osteocalcin concentrations are higher in children than in adults, rising during puberty and then falling to adult levels.100-102 Most studies show a higher concentration of osteocalcin in adult males than in adult females and show an age-related increase after the fifth decade of life in women. 42,103,104 The postmenopausal rise in serum osteocalcin can be reversed by hormone replacement therapy.35,105
REFERENCE RANGES
The majority of commercial kits supply reference ranges for serum osteocalcin. However, many of these data do not reflect the populations in which osteocalcin is most likely to be measured, such as postmenopausal women or children, and have been derived from a small sample of subjects. It is recommended that, once a laboratory has decided on which method to use, a local reference range is determined in the clinical population for which the assay is likely to be requested.
PROBLEMS WITH ASSAYS AND DIFFERENCES BETWEEN METHODS
In considering which method to employ there are certain factors that need to be considered. Firstly, a decision is needed regarding the use of radiolabelled or enzyme-labelled assays. For the majority of clinical chemistry laboratories, systems will be in place for safe working practices with radiation, but this incurs extra training costs, etc. The clinical interpretation of osteocalcin measurements relies, to a certain extent, upon methodological differences, but there is no consensus regarding the most clinically informative fragment(s) of osteocalcin to measure. This may depend on the patient groups for which the assay is requested. As stated earlier, there is no standardization of methods at present. It is strongly recommended that when a laboratory has decided on the assay most suited to its needs, a local reference range should be determined.
CONCLUSION
There is increasing demand for clinically relevant biochemical markers of bone health. Osteocalcin is one of the best characterized of the markers of bone formation. However, as this review indicates, it is unclear which assay system provides results with the greatest clinical utility.
The application of osteocalcin assays to routine clinical practice has been hampered by poor comparability between different methods and the instability and heterogeneity of circulating osteocalcin.Pr"
Osteocalcin assays are available in many formats using both polyclonal and monoclonal antibodies and different standards. Given this, it is not surprising that osteocalcin values determined by different assays give discordant results. The natural outcome of the research reported in the sections of this review on sample stability and biological variability is an absolute need for continuity in the methodology for sample collection. This includes the avoidance of haemolysis and freeze-thaw cycles.
The poor comparability of methods and problems with sample handling are compounded by a lack of consensus regarding the most clinically informative fragment(s) of osteocalcin. We suggest that this will depend on the patient group for which the assay is likely to be requested.
The establishment of a Quality Assurance scheme will aid considerably the standardization of methodologies. However, until there is consensus on which fragment(s) of osteocalcin to measure and the introduction of national or international standards, it is recommended that laboratories determine a local reference range with the system of their choice and establish standard operating procedures for continuity in the measurement of osteocalcin. 
